Executive Summary
Rating: BUY | BSX
Boston Scientific combines double-digit revenue growth with improving cash generation, but the investment case now hinges on execution around capital deployment and reimbursement resilience. In Q1 2026, revenue rose 11.6% year over year to $5,203.0M and EBITDA increased 32.3% to $1,603.0M, indicating operating leverage remains intact. The key strength is the breadth of its interventional portfolio and installed base across cardiovascular, endoscopy, urology, neuromodulation, electrophysiology, cardiac rhythm management, and interventional oncology. The main risk is reimbursement and pricing pressure, which can compress ASPs and procedure volumes. The near-term catalyst is continued conversion of revenue growth into cash flow, supported by TTM levered free cash flow of $2,807.1M.
Investment Rating
Rating: BUY
Boston Scientific trades at 14.5x EV/EBITDA and 12.6x forward P/E, with Q1 2026 revenue growth of 11.6% and EBITDA growth of 32.3%. That valuation is supported by TTM operating cash flow of $4,341.0M and levered free cash flow of $2,807.1M. The stock is not inexpensive, but the combination of growth, cash generation, and a diversified product base supports a premium multiple.
Company Profile
Boston Scientific develops, manufactures, and markets interventional medical devices used in cardiovascular, endoscopy, urology, neuromodulation, electrophysiology, cardiac rhythm management, and interventional oncology. Revenue is generated primarily through device sales to hospitals, clinics, outpatient facilities, and medical offices across 127 countries, supported by direct sales in major markets and distributors elsewhere. The company operates through two reportable segments, MedSurg and Cardiovascular, and is headquartered in Marlborough, Massachusetts. Its manufacturing and distribution sites are certified under ISO 13485.
Economic Moat
Business Model
Boston Scientific’s moat is built on regulatory approvals, clinical evidence, and physician workflow integration rather than on any single product. Devices such as WATCHMAN, FARAPULSE, and Intracept benefit from installed clinical familiarity, reimbursement pathways, and training infrastructure that are difficult for new entrants to replicate quickly. The company’s global sales network also supports launch execution across multiple specialties and geographies.
Risk Factors
A high-severity risk is reimbursement and pricing compression. Management has flagged continued consolidation in health care, government pricing controls, and site-of-service requirements as factors that can force price concessions and reduce procedure volumes.
A high-severity risk is regulatory delay or recall. FDA clearance, EU MDR compliance, and foreign recertification can take time, and adverse findings can lead to bans, seizures, recalls, or suspension of clearances.
A high-severity risk is product liability and litigation. Many devices are implanted for long periods, which increases the duration of exposure to claims and potential damages.
A medium-severity risk is supply-chain disruption. The company relies on single-source inputs in some cases, and alternative vendor qualification can be slow. Sterilization and materials regulation also create operational complexity.
A medium-severity risk is leverage after acquisitions. Total debt was $11,029.0M at the most recent quarter, and further deal-related borrowing could reduce balance-sheet flexibility if integration or reimbursement trends disappoint.
Management Discussion & Analysis
Management’s tone suggests capital allocation remains acquisition-led, with R&D and restructuring running in parallel. The company closed Nalu Medical on January 27, 2026 for $517.0M and agreed to acquire Penumbra for $14.5B, with $11.0B funded by cash and new debt and the balance in stock. That structure implies management is willing to increase leverage to expand scale in cardiovascular devices.
At the same time, R&D spending rose to $2.1B in 2025, or 10.2% of sales, showing continued investment in pipeline depth. The 2023 restructuring plan was also expanded by $250.0M to a total of $700.0M to $800.0M, indicating management is still simplifying manufacturing and overhead while funding growth initiatives.
Recent Earnings
The latest quarter showed a favorable mix of top-line growth and margin expansion. Revenue increased 11.6% year over year to $5,203.0M in Q1 2026, while EBITDA rose 32.3% to $1,603.0M and net income increased 99.0% to $1,341.0M. The sequential decline from $5,286.0M in Q4 2025 to $5,203.0M in Q1 2026 has no clear driver identified; investors should seek further disclosure. Even so, the quarter suggests pricing and mix remained supportive enough to lift earnings faster than sales.
Financial Analysis
Growth
BSX — Financial Growth (Quarterly, USD Mil)
Source: Yahoo Finance — Quarterly Financial Statements
| Metric | 2025-03-31 | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|---|
| REVENUE (USD Mil) | 4,663.000 | 5,061.000 | 5,065.000 | 5,286.000 | 5,203.000 |
| EBIT (USD Mil) | 887.000 | 1,031.000 | 1,026.000 | 790.000 | 1,252.000 |
| EBITDA (USD Mil) | 1,212.000 | 1,367.000 | 1,368.000 | 1,155.000 | 1,603.000 |
| NET INCOME (USD Mil) | 674.000 | 797.000 | 755.000 | 672.000 | 1,341.000 |
| DILUTED EPS | 0.450 | 0.530 | 0.510 | 0.450 | 0.900 |
Revenue increased from $4,663.0M in Q1 2025 to $5,203.0M in Q1 2026, up 11.6% year over year. EBITDA grew faster than revenue, rising 32.3% to $1,603.0M, which points to operating leverage. Net income also accelerated, reaching $1,341.0M in Q1 2026, up 99.0% year over year. Diluted EPS was 0.90 in Q1 2026.
Profitability
BSX — Profitability (TTM)
Source: Yahoo Finance — Trailing Twelve Months (TTM)
| Metric | TTM |
|---|---|
| Operating Margin (TTM) | 0.206 |
| Net Margin (TTM) | 0.173 |
| Return on Assets (TTM) | 0.061 |
| Return on Equity (TTM) | 0.147 |
TTM operating margin was 20.6%, net margin was 17.3%, return on assets was 6.1%, and return on equity was 14.7%. The margin profile is solid for a large-cap medtech company and indicates that revenue growth is converting into earnings rather than being absorbed by overhead. ROE is the strongest return metric in the set, reflecting efficient use of equity capital.
Valuation
BSX — Valuation Multiples
Source: Yahoo Finance
| Metric | Value |
|---|---|
| Market Cap (USD Mil) | 69,724.922 |
| Enterprise Value (USD Mil) | 79,540.920 |
| Trailing P/E | 19.628 |
| Forward P/E | 12.594 |
| Price/Sales (TTM) | 3.382 |
| Price/Book (mrq) | 2.696 |
| EV/Revenue | 3.859 |
| EV/EBITDA | 14.462 |
| Beta (5Y Monthly) | 0.559 |
Boston Scientific trades at 19.6x trailing P/E, 12.6x forward P/E, 3.4x price/sales, 2.7x price/book, 3.9x EV/revenue, and 14.5x EV/EBITDA. Market cap is $69,724.9M and enterprise value is $79,540.9M. Beta is 0.6, which is consistent with a lower-volatility large-cap health care name. The valuation is not cheap, but it is supported by double-digit revenue growth and strong cash generation.
Leverage
BSX — Leverage & Coverage (Quarterly)
Source: Yahoo Finance — Quarterly Financial Statements
| Metric | Value |
|---|---|
| Total Debt/Equity % (mrq) | 42.250 |
| Current Ratio (mrq) | 1.900 |
| Total Debt (mrq, USD Mil) | 11,029.000 |
| Operating Cash Flow (TTM, USD Mil) | 4,341.000 |
| Levered Free Cash Flow (TTM, USD Mil) | 2,807.125 |
Total debt/equity was 42.2% at the most recent quarter, current ratio was 1.9x, and total debt was $11,029.0M. Operating cash flow was $4,341.0M on a TTM basis, and levered free cash flow was $2,807.1M. That leaves the balance sheet manageable, with enough liquidity to support R&D, integration costs, and debt service.
Comparable Analysis
Boston Scientific’s 11.6% TTM revenue growth is above MDT at 9.9%, ABT at 7.8%, SYK at 2.6%, and ZBH at 9.3%, but below EW at 16.7%. On profitability, BSX’s 20.6% operating margin and 17.3% net margin compare favorably with MDT, ABT, SYK, and ZBH, though EW remains the margin leader on operating income. On leverage, BSX’s 42.2% debt/equity is below MDT, ABT, SYK, and ZBH, but above EW’s 6.8%, leaving BSX in the middle of the group on balance-sheet risk.
Valuation is also mid-pack. BSX’s 19.6x trailing P/E and 3.9x EV/revenue are below EW and SYK, but above ZBH on EV/revenue and below ABT on P/E. The market is therefore paying for a combination of growth, profitability, and relative balance-sheet discipline rather than for the highest growth or the lowest multiple.
Growth
| Company | Revenue TTM (USD Mil) | Revenue Growth YoY % | EBITDA TTM (USD Mil) | Diluted EPS TTM |
|---|---|---|---|---|
| BSX | 20,614.000 | 0.116 | 5,500.000 | 2.390 |
| MDT | 36,364.000 | 0.099 | 10,081.000 | 3.730 |
| EW | 6,303.500 | 0.167 | 1,903.600 | 1.850 |
| ABT | 45,134.000 | 0.078 | 11,744.000 | 3.570 |
| SYK | 25,270.000 | 0.026 | 6,918.000 | 8.650 |
| ZBH | 8,409.100 | 0.093 | 2,581.000 | 3.860 |
Valuation
| Company | Trailing P/E | Forward P/E | EV/Revenue | EV/EBITDA | Price/Sales (TTM) | Price/Book (mrq) | Market Cap (USD Mil) | Enterprise Value (USD Mil) | Beta (5Y Monthly) |
|---|---|---|---|---|---|---|---|---|---|
| BSX | 19.628 | 12.594 | 3.859 | 14.462 | 3.382 | 2.696 | 69,724.920 | 79,540.920 | 0.559 |
| MDT | 21.501 | 12.517 | 3.379 | 12.188 | 2.832 | 2.101 | 102,967.570 | 122,866.570 | 0.597 |
| EW | 46.005 | 25.273 | 7.304 | 24.185 | 7.774 | 4.755 | 49,006.340 | 46,037.740 | 0.866 |
| ABT | 24.700 | 14.553 | 4.012 | 15.418 | 3.403 | 2.950 | 153,593.090 | 181,074.020 | 0.620 |
| SYK | 36.092 | 18.668 | 5.222 | 19.074 | 4.736 | 5.326 | 119,685.230 | 131,954.230 | 0.785 |
| ZBH | 22.946 | 9.852 | 2.884 | 9.396 | 2.038 | 1.352 | 17,134.970 | 24,251.670 | 0.472 |
Profitability
| Company | Operating Margin (TTM) | Net Margin (TTM) | Return on Assets (TTM) | Return on Equity (TTM) |
|---|---|---|---|---|
| BSX | 0.206 | 0.173 | 0.061 | 0.147 |
| MDT | 0.213 | 0.132 | — | 0.099 |
| EW | 0.312 | 0.174 | 0.083 | 0.105 |
| ABT | 0.135 | 0.139 | 0.056 | 0.123 |
| SYK | 0.178 | 0.132 | 0.077 | 0.152 |
| ZBH | 0.197 | 0.091 | 0.041 | 0.061 |
Leverage
| Company | Total Debt/Equity % (mrq) | Current Ratio (mrq) | Total Debt (mrq, USD Mil) | Operating Cash Flow TTM (USD Mil) | Free Cash Flow TTM (USD Mil) |
|---|---|---|---|---|---|
| BSX | 42.250 | 1.900 | 11,029.000 | 4,341.000 | 2,807.120 |
| MDT | 57.060 | — | 28,071.000 | 7,330.000 | — |
| EW | 6.806 | 4.421 | 702.900 | 1,358.600 | 902.140 |
| ABT | 64.773 | 1.388 | 34,136.000 | 9,464.000 | 6,341.130 |
| SYK | 66.295 | 2.112 | 15,234.000 | 5,375.000 | 4,359.880 |
| ZBH | 59.827 | 1.733 | 7,587.000 | 1,673.700 | 1,044.120 |
Returns
| Company | Return on Equity (TTM) | Return on Assets (TTM) |
|---|---|---|
| BSX | 0.147 | 0.061 |
| MDT | 0.099 | — |
| EW | 0.105 | 0.083 |
| ABT | 0.123 | 0.056 |
| SYK | 0.152 | 0.077 |
| ZBH | 0.061 | 0.041 |
Source: Yahoo Finance
Conclusion
Boston Scientific remains a constructive investment case because growth, profitability, and cash flow are all moving in the right direction. Q1 2026 showed 11.6% revenue growth, 32.3% EBITDA growth, and 99.0% net income growth, while TTM free cash flow remained strong at $2,807.1M. The stock’s valuation is reasonable for a company with this operating profile, but the key swing factors are reimbursement pressure and execution on acquisition-led expansion. If management can preserve margin expansion while integrating new assets, the current multiple should remain defensible.
Data sourced from Yahoo Finance. Not investment advice.
Leave a Reply